Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III

Top-Line Psoriasis Efficacy Bested Placebo; Safety Similar To Phase II

Nov 04 2020

• By Mandy Jackson

Listen to this article

Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.

Dart arrow hitting in the target center of dartboard using as background Target business, achieve and victory,success concept. — Oral TYK2 inhibitor deucravacitinib (BMS-986165) met both primary endpoints in its first Phase III psoriasis study

Bristol Myers Squibb Company confirmed on 3 November that its oral TYK2 inhibitor deucravacitinib (BMS-986165) is likely to be a formidable competitor in the treatment of psoriasis for Amgen, Inc.’s Otezla (apremilast), the oral Celgene Corporation-developed PDE4 inhibitor that BMS sold to Amgen for $13.4bn to gain US Federal Trade Commission clearance of its $74bn acquisition of Celgene last year.

Bristol reported top-line results from the first of two pivotal Phase III clinical trials for deucravacitinib in moderate-to-severe psoriasis and,...

More from Dermatological

Galderma Gets First Biologic To Market With Nemluvio Approval
Mar 10 2025
• By Jessica Merrill
Nemluvio is a first-in-class IL-31 inhibitor that the US FDA approved for prurigo nodularis.
Dupixent Data Could Scratch A Regulatory Itch
Sep 13 2024
• By Elizabeth Cairns
New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.
Leo Shrugs Off Timber Drug Failure As Revenues Roar
Aug 27 2024
• By Kevin Grogan
The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.
Leo’s Congenital Ichthyosis Candidate Fails Phase III Study
Aug 21 2024
• By Joseph Haas
TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.